Treatment of pemphigus vulgaris: part 1 – current therapies

References

• Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.
   PubMed Web of Science ®Google Scholar
• Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–427.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Cozzani E, Carrozzo M, et al. Urban legends: pemphigus vulgaris. Oral Dis. 2012;18:442–458.
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs. 2004;13:1019–1032.
   PubMed Web of Science ®Google Scholar
• Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405–414.
   PubMed Web of Science ®Google Scholar
• Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757–778.
   PubMed Web of Science ®Google Scholar
• Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:833–844.
   PubMed Web of Science ®Google Scholar
• Kar PK. Recent trends in the management of pemphigus vulgaris. Med J Armed Forces India. 1998;54:243–246.
   PubMedGoogle Scholar
• Kusljic S, Manias E, Gogos A. Corticosteroid-induced psychiatric disturbances: it is time for pharmacists to take notice. Res Social Adm Pharm. 2016;12:355–360.
   PubMed Web of Science ®Google Scholar
• Hall RC, Popkin MK, Stickney SK, et al. Presentation of the steroid psychoses. J Nerv Ment Dis. 1979;167:229–236.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5:319–332.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124.
   PubMed Web of Science ®Google Scholar
• Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157:142–148.
   PubMed Web of Science ®Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963.
   PubMedGoogle Scholar
• Schadt CJS. Glucocorticoids. Dermatology. 4th ed. Philadelphia: Elsevier; 2017. p. 2186–2199.
   Google Scholar
• López-Serrano P, de la Fuente Briongos E, Alonso EC, et al. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539–547.
   PubMed Web of Science ®Google Scholar
• Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383:2152–2167.
   PubMed Web of Science ®Google Scholar
• Joseph RM, Hunter AL, Ray DW, et al. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46:133–141.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17:913–916.
   PubMedGoogle Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–248.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39:1383–1389.
   PubMed Web of Science ®Google Scholar
• Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859–865.
   PubMed Web of Science ®Google Scholar
• Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213–1224.
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:72–75.
   PubMed Web of Science ®Google Scholar
• Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond). 1981;61(Suppl 7):381s–383s.
   PubMedGoogle Scholar
• Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.
   PubMedGoogle Scholar
• Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980;98:1773–1777.
   PubMed Web of Science ®Google Scholar
• Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int. 1996;50:538–542.
   PubMed Web of Science ®Google Scholar
• Luo X, Feng H, Jiang L, et al. Abnormal uterine bleeding induced by glucocorticoid treatment for pemphigus. Case series and proposed treatment algorithm. Saudi Med J. 2016;37:1025–1028.
   PubMed Web of Science ®Google Scholar
• Suh-Burgmann E, Hung YY, Mura J. Abnormal vaginal bleeding after epidural steroid injection: a paired observation cohort study. Am J Obstet Gynecol. 2013;209:206.e1–206.e6.
   PubMed Web of Science ®Google Scholar
• Harman KE, Brown D, Exton LS, et al. British association of dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177:1170–1201.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018:S0190-9622(18)30207-X. DOI:10.1016/j.jaad.2018.02.021.
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–837.
   PubMed Web of Science ®Google Scholar
• Schutz S, Newhouse R, Russo JD. Alternate-day steroid regimen in the treatment of ocular disease. Br J Ophthalmol. 1968;52:461.
   PubMed Web of Science ®Google Scholar
• Easton JG, Busser RJ, Heimlich EM. Effect of alternate-day steroid administration on adrenal function in allergic children. J Allergy Clin Immunol. 1971;48:355–360.
   PubMed Web of Science ®Google Scholar
• Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician. 1998;58:443–450.
   PubMed Web of Science ®Google Scholar
• Campbell AM, Martin JR, Erstad BL. Corticosteroid tapering regimens in rheumatic disease: a systematic review. J Clin Rheumatol. 2018;1. DOI:10.1097/RHU.0000000000000917. PMID:30363001
   Web of Science ®Google Scholar
• Pedrosa MC, Rohrer RM, Kaplan MM. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Clin Transplant. 1995;9:322–325.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
   PubMed Web of Science ®Google Scholar
• Mimouni D, Bar H, Gdalevich M, et al. Pemphigus, analysis of 155 patients. J Eur Acad Dermatol Venereol. 2010;24:947–952.
   PubMed Web of Science ®Google Scholar
• Pincus T, Castrejon I, Sokka T. Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol. 2011;29:S130–S138.
   PubMed Web of Science ®Google Scholar
• Almugairen N, Hospital V, Bedane C, et al. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69:583–588.
   PubMed Web of Science ®Google Scholar
• Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol. 1995;20:363–370.
   PubMed Web of Science ®Google Scholar
• Bickers D, Hazen PG, Lynch W. Clinical pharmacology of skin diseases. New York (NY): Churchill Livingstone; 1984.
   Google Scholar
• Pharmacists ASoH, editor. American hospital formulary service drug information. Maryland (USA): Bethesda; 1990.
   Google Scholar
• Zaynoun ST, Salti IS. The effect of intracutaneous glucocorticoids on plasma cortisol levels. Br J Dermatol. 1973;88:151–156.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Ahmed AR. Pemphigus vulgaris localized to the tongue. J Dermatol Case Rep. 2014;8:55–57.
   PubMedGoogle Scholar
• Sami N, Ahmed AR. Penile pemphigus. Arch Dermatol. 2001;137:756–758.
   PubMedGoogle Scholar
• Engineer L, Norton LA, Ahmed AR. Nail involvement in pemphigus vulgaris. J Am Acad Dermatol. 2000;43:529–535.
   PubMed Web of Science ®Google Scholar
• Daoud YJ, Cervantes R, Foster CS, et al. Ocular pemphigus. J Am Acad Dermatol. 2005;53:585–590.
   PubMed Web of Science ®Google Scholar
• Malik M, El Tal AE, Ahmed AR. Anal involvement in pemphigus vulgaris. Dis Colon Rectum. 2006;49:500–506.
   PubMed Web of Science ®Google Scholar
• Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85–92.
   PubMed Web of Science ®Google Scholar
• Atzmony L, Hodak E, Leshem YA, et al. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:264–271.
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739–742.
   PubMed Web of Science ®Google Scholar
• Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–628.
   PubMed Web of Science ®Google Scholar
• Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447–1454.
   PubMed Web of Science ®Google Scholar
• Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–908.
   PubMed Web of Science ®Google Scholar
• Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138–145.
   PubMed Web of Science ®Google Scholar
• Mabrouk D, Gurcan HM, Keskin DB, et al. Association between cancer and immunosuppressive therapy–analysis of selected studies in pemphigus and pemphigoid. Ann Pharmacother. 2010;44:1770–1776.
   PubMed Web of Science ®Google Scholar
• Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136–142.
   PubMedGoogle Scholar
• Chrysomallis F, Ioannides D, Teknetzis A, et al. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33:803–807.
   PubMed Web of Science ®Google Scholar
• Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75:271–284.
   PubMed Web of Science ®Google Scholar
• Dieterle A, Abeywickrama K, von Graffenried B. Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. Transplant Proc. 1988;20:349–355.
   PubMed Web of Science ®Google Scholar
• Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National high blood pressure education program. Arch Intern Med. 1990;150:280–283.
   PubMed Web of Science ®Google Scholar
• Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161:723–731.
   PubMed Web of Science ®Google Scholar
• Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22:83–87.
   PubMed Web of Science ®Google Scholar
• Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988;68:413–421.
   PubMed Web of Science ®Google Scholar
• Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169:916–921.
   PubMed Web of Science ®Google Scholar
• Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972;106:491–497.
   PubMedGoogle Scholar
• Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother. 2008;9:1519–1530.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, De D. Pemphigus in India. Indian J Dermatol Venereol Leprol. 2011;77:439–449.
   PubMed Web of Science ®Google Scholar
• White KP, Driscoll MS, Rothe MJ, et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30:768–773.
   PubMed Web of Science ®Google Scholar
• Handa S, Singh G, Arora AK, et al. Effect of intravenous pulse dexamethasone versus daily oral prednisolone on bone mineral density in dermatology patients: is it a site-specific response? Indian J Dermatol Venereol Leprol. 2018;84:174–178.
   PubMed Web of Science ®Google Scholar
• Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923–4928.
   PubMed Web of Science ®Google Scholar
• Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol. 1978;98:243.
   PubMed Web of Science ®Google Scholar
• Ranugha PS, Kumari R, Kartha LB, et al. Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. Indian J Dermatol Venereol Leprol. 2012;78:508–510.
   PubMed Web of Science ®Google Scholar
• Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058–1064.
   PubMed Web of Science ®Google Scholar
• Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22:35–40.
   PubMed Web of Science ®Google Scholar
• Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429–452.
   PubMed Web of Science ®Google Scholar
• Salahuddin H, Sheikh AA, Hussaini S, et al. Ischemic stroke after plasmapheresis. Am J Med Sci. 2018;356:399–403.
   PubMed Web of Science ®Google Scholar
• Amber KT, Maglie R, Solimani F, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78:1527–1548.
   PubMed Web of Science ®Google Scholar
• Behzad M, Mobs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–852.
   PubMed Web of Science ®Google Scholar